Telix and ITM Join Forces to Create Radiopharma Powerhouse

Key points

• Creates a leading radiopharmaceutical company with enhanced capabilities
• Enhances supply chain and strengthens EBITDA
• Provides access to commercial therapeutic market upon regulatory approval of ITM-11
• Expected to be EBITDA positive from FY 2027 onward

Full summary

Telix Pharmaceuticals Ltd and ITM Isotope Technologies Munich SE have announced a strategic merger to create a leading radiopharmaceutical company with enhanced capabilities across the value chain. The merger will enhance efficiencies, add a profitable manufacturing business, and strengthen the supply chain. The combined entity will have a robust therapeutic pipeline, including ITM-11, which has the potential to accelerate entry into the commercial therapeutic market. The transaction is expected to be EBITDA positive from FY 2027 onward. The merger is expected to close by the end of FY 2026, subject to shareholder approval.

Guidance

Expected to be EBITDA positive from FY 2027 onward

Outlook

The merger is expected to position the combined entity for long-term leadership in the rapidly growing radiopharmaceutical industry, with significant growth potential in the therapeutic and diagnostic radioisotope markets.